Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "retinal-diseases"

14 News Found

ASG opens its branch of super-specialty eye hospitals in Noida
Healthcare | May 21, 2024

ASG opens its branch of super-specialty eye hospitals in Noida

ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad

Dr. Agarwal's Health Care raises US$80 mn from TPG and Temasek to expand network to 300 hospitals
Healthcare | August 20, 2023

Dr. Agarwal's Health Care raises US$80 mn from TPG and Temasek to expand network to 300 hospitals

The company has new projects in development in Mumbai, Punjab, central and northern India, among others

Grand Opening of Kodiak Sciences’ bioconjugation facility
Biotech | May 19, 2022

Grand Opening of Kodiak Sciences’ bioconjugation facility

Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn
Biotech | December 22, 2021

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn

Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy

Latest Stories

Wockhardt submits NDA to USFDA for Zidebactam-Cefepime injection

FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer

AbbVie’s Natrelle awarded supplier agreement from Vizient

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging